Since the need for new drugs is particularly urgent for severe Gram negative
hospital infections, NABATIVI will make a special effort to fill this gap. The strategy is focused around three main objectives
. Using P. aeruginosa
and B. cenocepacia
as gram-negative model organisms, NABATIVI aims:
- To identify novel antibacterial and antibiotic re-sensitivisation targets in antibiotic resistant strains using genomic approaches.
- To validate these targets in strains of various clinical origin using a number of in vitro and in vivo disease models.
- To inhibit the targets by optimized lead compounds from synthetic and natural sources.
Research project will address both new molecular targets in pathogens and identification of new compounds derived from synthetic and natural sources, but also a better knowledge of basic bacterial physiology and pathogenesis.